Metacrine, Inc. (MTCR)
|Net Income (ttm)||n/a|
|Trading Day||February 25|
|Day's Range||8.38 - 8.93|
|52-Week Range||7.64 - 16.19|
There are some investors who purchase stocks that are trading below their liquidation value because they believe they can make impressive gains out of their investments after the market has re...
Metacrine Announces Publication of MET409 NASH Proof-of-Concept Study Results in the Journal of Hepatology
Publication highlights the first clinical evidence that the risk-benefit profile of FXR agonists can be enhanced through structural optimization Publication highlights the first clinical evide...
SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patie...
Metacrine Initiates Phase 2a Combination Trial of MET409 with Empagliflozin in Patients with Type 2 Diabetes and NASH
Trial Designed to Evaluate Potential of FXR-Based Combination Therapy in a Growing Segment of NASH Patient Population with Significant Unmet Needs Trial Designed to Evaluate Potential of FXR-B...
MET642 Demonstrated Sustained Pharmacokinetic Profile and Robust FXR Target Engagement with Once-Daily Oral Dosing, without Pruritis or LDL-Cholesterol Increase
SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patie...
Upcoming Data at AASLD Support Robust, Sustained FXR Activation by MET409 in Patients with NASH
Metacrine to Present New Data from MET409 Program in NASH at AASLD’s The Liver Meeting Digital Experience™
New Data Support Robust, Sustained FXR Activation by MET409 in Patients with NASH and Demonstrate Predictability of Liver Fat Reductions as Early as Week 4 of Treatment New Data Support Robust...
Did you miss the Metacrine IPO? No worries.
Shares of Metacrine Inc. got a bullish start to their public life, as they opened 10.7% their initial public offering price.
Metacrine, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with liver and gastrointestinal diseases in the United States. It is developing MET409, a therapy that is in a Phase Ib proof-of-concept clinical trial for the treatment of non-alcoholic steatohepatitis patients; and MET642, a candidate, which is in Phase 1 clinical trial for the treatment of non-alcoholic steatohepatitis patients. The company has a research collaboration with Novo Nordisk A/S to perform research activities relate... [Read more...]
|IPO Date |
Sep 16, 2020
|Stock Exchange |
|Ticker Symbol |
According to 4 analysts, the average rating for Metacrine stock is "Strong Buy." The 12-month stock price forecast is 20.50, which is an increase of 142.89% from the latest price.